¼¿ï´ëÇб³º´¿ø ´ëÇÑÇ÷¾×ÇÐȸ 2019 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸ ¸ðÀÓ : 2019-06-01 |
|
¼¿ï´ëÇб³º´¿ø ´ëÇÑÇ÷¾×ÇÐȸ 2019 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸ ¸ðÀÓ : 2019-06-01 ±³À°ÀÏÀÚ : 2019-06-01 ±³À°Àå¼Ò : ¼¿ï´ëÇб³º´¿ø ÀÇÇבּ¸Çõ½Å¼¾ÅÍ(CMI) 1Ãþ ¼¼ºÈ¯¿¬±¸È¦ ±³À°ÁÖÁ¦ : 2019 »ó¹Ý±â KMMWP workshop & Àӻ󿬱¸ ¸ðÀÓ ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ ½ÃÇà±â°ü(ÁöºÎ/°ú) : ´Ù¹ß°ñ¼öÁ¾¿¬±¸È¸ ´ã´çÀÚ : ¼È¿Áø ¿¬¶ôó : 02-516-6581 À̸ÞÀÏ : kmmwp_office@naver.com ±³À°Á¾·ù : ³»°ú, Áø´Ü°Ë»çÀÇÇаú Âü¼®¿¹»óÀοø : 100¸í Èñ¸ÁÆòÁ¡ : 5Á¡ Áö¿ª : ¼¿ïƯº°½Ã ±³À°½Ã°£ : 5 ½Ã°£ 0ºÐ ¼¼ºÎ¼ö°·á : 0¿ø ºñ°í ±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 10:30~10:50 Infection control for MM patients Á¤¼ºÈÆ(Àü³²ÀÇ´ë) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 10:50~11:10 Management of bone disease: bisphosphonates vs. denosumab ±ÇÁöÇö(ÃæºÏÀÇ´ë) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 11:10~11:30 Tools for assessing frailty ÀÌÈ£¼·(°í½ÅÀÇ´ë) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 11:30~12:00 Incorporation of novel agents in the ting of autologous stem cell transplantation ±è´ë½Ä(°í·ÁÀÇ´ë) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 12:00~12:30 Comparison of partners for Rd for the management of RRMM: antibodies vs. proteasome inhibitors ÀÌÀ¯Áø(¿ï»êÀÇ´ë) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 13:30~14:20 Effective treatment of RRMM: myeloma by BCMA-specific chimeric antigen receptor-modified T cells Liu Yuan fang(University of Jiao Tong, China) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 14:30~15:20 Currently active KMMWP protocol ±è±âÇö(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 06-01 ¼¼ºÈ¯¿¬±¸È¦ 15:30~16:50 2019 KMMWP new protocol proposal ±èÁø¼®(¿¬¼¼ÀÇ´ë) |
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|